Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Dr. Chadi Nabhan, Oncology Specialists, S.C.

ClinicalTrials.gov Identifier:

NCT00272038

First received: January 3, 2006

Last updated: December 7, 2012

Last verified: December 2012

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	October 2010
Primary Completion Date:	October 2010 (Final data collection date for primary outcome measure)

No publications provided by Oncology Specialists, S.C.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Nabhan C, Lestingi TM, Galvez A, Tolzien K, Kelby SK, Tsarwhas D, Newman S, Bitran JD. Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial. Urology. 2009 Sep;74(3):665-71. Epub 2009 Jul 17.

To Top